New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly emerging insulin-independent anti-hyperglycemic agents that work independently of β-cells. Quite a few large-scale clinical trials have proven the cardiovascular protective function of SGLT2is in both diabetic and non-diabetic patients. B...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.903902/full |
| _version_ | 1811261886236196864 |
|---|---|
| author | Juexing Li Juexing Li Lei Zhou Lei Zhou Hui Gong Hui Gong |
| author_facet | Juexing Li Juexing Li Lei Zhou Lei Zhou Hui Gong Hui Gong |
| author_sort | Juexing Li |
| collection | DOAJ |
| description | Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly emerging insulin-independent anti-hyperglycemic agents that work independently of β-cells. Quite a few large-scale clinical trials have proven the cardiovascular protective function of SGLT2is in both diabetic and non-diabetic patients. By searching all relevant terms related to our topics over the previous 3 years, including all the names of agents and their brands in PubMed, here we review the mechanisms underlying the improvement of heart failure. We also discuss the interaction of various mechanisms proposed by diverse works of literature, including corresponding and opposing viewpoints to support each subtopic. The regulation of diuresis, sodium excretion, weight loss, better blood pressure control, stimulation of hematocrit and erythropoietin, metabolism remodeling, protection from structural dysregulation, and other potential mechanisms of SGLT2i contributing to heart failure improvement have all been discussed in this manuscript. Although some remain debatable or even contradictory, those newly emerging agents hold great promise for the future in cardiology-related therapies, and more research needs to be conducted to confirm their functionality, particularly in metabolism, Na+-H+ exchange protein, and myeloid angiogenic cells. |
| first_indexed | 2024-04-12T19:13:57Z |
| format | Article |
| id | doaj.art-bc22c939f15b4a2282d0438af09095ff |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T19:13:57Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-bc22c939f15b4a2282d0438af09095ff2022-12-22T03:19:48ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-09-01910.3389/fcvm.2022.903902903902New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failureJuexing Li0Juexing Li1Lei Zhou2Lei Zhou3Hui Gong4Hui Gong5Department of Cardiology, Jinshan Hospital of Fudan University, Shanghai, ChinaDepartment of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Cardiology, Jinshan Hospital of Fudan University, Shanghai, ChinaDepartment of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Cardiology, Jinshan Hospital of Fudan University, Shanghai, ChinaDepartment of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, ChinaSodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly emerging insulin-independent anti-hyperglycemic agents that work independently of β-cells. Quite a few large-scale clinical trials have proven the cardiovascular protective function of SGLT2is in both diabetic and non-diabetic patients. By searching all relevant terms related to our topics over the previous 3 years, including all the names of agents and their brands in PubMed, here we review the mechanisms underlying the improvement of heart failure. We also discuss the interaction of various mechanisms proposed by diverse works of literature, including corresponding and opposing viewpoints to support each subtopic. The regulation of diuresis, sodium excretion, weight loss, better blood pressure control, stimulation of hematocrit and erythropoietin, metabolism remodeling, protection from structural dysregulation, and other potential mechanisms of SGLT2i contributing to heart failure improvement have all been discussed in this manuscript. Although some remain debatable or even contradictory, those newly emerging agents hold great promise for the future in cardiology-related therapies, and more research needs to be conducted to confirm their functionality, particularly in metabolism, Na+-H+ exchange protein, and myeloid angiogenic cells.https://www.frontiersin.org/articles/10.3389/fcvm.2022.903902/fullheart failuremechanismsmetabolismsodium-glucose cotransporter 2 inhibitors (SGLT2is)diabetes |
| spellingShingle | Juexing Li Juexing Li Lei Zhou Lei Zhou Hui Gong Hui Gong New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure Frontiers in Cardiovascular Medicine heart failure mechanisms metabolism sodium-glucose cotransporter 2 inhibitors (SGLT2is) diabetes |
| title | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure |
| title_full | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure |
| title_fullStr | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure |
| title_full_unstemmed | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure |
| title_short | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure |
| title_sort | new insights and advances of sodium glucose cotransporter 2 inhibitors in heart failure |
| topic | heart failure mechanisms metabolism sodium-glucose cotransporter 2 inhibitors (SGLT2is) diabetes |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.903902/full |
| work_keys_str_mv | AT juexingli newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure AT juexingli newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure AT leizhou newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure AT leizhou newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure AT huigong newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure AT huigong newinsightsandadvancesofsodiumglucosecotransporter2inhibitorsinheartfailure |